September 23, 2020
The Drugs Controller General of India has approved the commercial launch of ‘Feluda’, the Tata CRISPR COVID-19 test. This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus. The technology has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology).
FELUDA, received regulatory approvals from DCGI for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting novel coronavirus,” the statement said.
The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing COVID-19.
Commenting on the development, Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd said, “The approval for the Tata CRISPR test for COVID-19 will give a boost to the country’s efforts in fighting the global pandemic.
“The commercialisation of Tata CRISPR test reflects the tremendous R&D talent in the country which can collaborate to transform India’s contributions to the global healthcare and scientific research world,” he said.
Anurag Agrawal, director, CSIR-IGIB, said the work started by CSIR under the sickle cell mission for genome diagnostics and therapeutics led to new knowledge that could be harnessed to quickly develop new diagnostic test for SARS-CoV-2.